Search Results

NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.

BlueSphere Bio, a drug development company focused on novel T-cell receptor (TCR) based therapies for oncology and non-oncology indications, today announced a collaboration with NMDP BioTherapies℠ (formerly Be The Match BioTherapies), an organization offering solutions for companies developing and commercializing cell and gene therapies, to advance BlueSphere’s first clinical trial evaluating a novel cell therapy for patients with high-risk leukemias.

NMDP BioTherapies℠ (formerly known as Be The Match BioTherapies) will present a poster at this year’s International Society for Cell & Gene Therapy annual meeting in Vancouver, Canada (ISCT 2024 ) sharing results of a study of the impacts of delayed whole blood processing on the stability of infectious disease marker analytes during donor qualification for allogeneic cell therapies.

NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president, leading the organization into its promising future phase.

The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the return of the Biotherapies Pavilion at the 2024 AABB Annual Meeting, which will take place Oct. 19-22 in Houston, Texas.

NMDP℠, a global nonprofit leader in cell therapy, and CIBMTR® (Center for International Blood and Marrow Transplant Research®) will present new data on hematopoietic cell transplantation (HCT) treatment effects in patients with hematological malignancies at the American Society of Clinical Oncology (ASCO) Annual Meeting May 31–June 4, 2024, in Chicago, Ill., and online.

NMDP BioTherapies announced today that CIBMTR CRO Services now offers a rapid clinical site selection and activation service, resulting in faster trial enrollment for cell and gene therapy (CGT) trials.

The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce several new offerings as part of its Certified Advanced Biotherapies Professional (CABP)

Cambridge Biotherapies proudly announces the launch of Ketamine Infusions for Pain and Headache Management, now available at all locations.

Underscoring its commitment to expanding access to cell and gene therapy, NMDP/Be The Match® presented research at the American Society of Hematology Annual Meeting & Exhibition, which demonstrated that the use of post-transplant cyclophosphamide based graft-versus-host disease prevention significantly reduces the risk of transplant across the human leukocyte antigen barrier and has the potential to level the playing field for patients with mismatched donors.